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We have identiﬁed four different mutations causing leukocyte adhesion deﬁciency (LAD) in the ITGB2 gene of patients from a
highly inbred population. Two were novel single-bp deletions (1497delG and 1920delG) causing frame shift and the two others
were the missense mutations G284S and R593C. In our study, the G284S was a recurrent mutation while the R593C occurred de
novo. We have also characterized a novel Xba1 polymorphic site located at the 5  end of the ITGB2 locus. Family studies showed
that the 1497delG mutation segregated with this marker and the intragenic AvaII polymorphic marker,suggesting the presence of a
founder effect. The observation of a heterogeneous spectrum including de novo and recurrent mutations causing LAD in a highly
inbred population is rather unexpected. In view of the literature published on the molecular genetics of LAD and considering the
ethnic origin of the patients studied, our ﬁndings conﬁrm the heterogeneity of the mutations causing LAD and point out potential
mutational hot spots in the ITGB2 gene.
INTRODUCTION
Leukocyte adhesion deﬁciency (LAD) is a primary im-
munedeﬁciency inherited as a rare autosomal, recessive ge-
netic disorder. Clinically LAD is characterized by a delayed
umbilical cord separation, recurrent life-threatening infec-
tions, impaired pus formation, poor wound healing, and
persistant leukocytosis. These clinical features are due to
defective leukocyte adhesion to endothelial cells, absence
of transmigration into inﬂammed tissues as well as deﬁ-
cient phagocytosis and chemotaxis [1]. Patients with LAD
have impaired cell surface expression of the leukocytes
speciﬁc adhesion molecules or β2 integrin heterodimers
[2]: LFA-1 (CD11a/CD18), Mac-1 or CR3 (CD11b/CD18),
p150/95 (CD11c/CD18) and probably the newly described
CD11d/CD18 molecule [3], due to heterogeneous defect in
the common β2(CD18) subunit. LAD clinical expression is
however heterogeneous and the disease course can be severe
ormoderatedependingonthelevelof β2integrinsthepatient
leukocytes express [4]. The assessment of the ITGB2 (CD18)
gene mRNA size and expression level along with the study of
the CD18precursorproteindeﬁneﬁvedifferenttypesof LAD
[5]. Mutational studies of β2 integrins deﬁcient patients of
different ethnic origins have disclosed molecular genetic het-
erogeneity underlying the disease and helped getting new in-
sights into β2 integrin structure-function. Several mutations
scattered throughout the ITGB2 gene have been described,
some of which resulted in single amino acid changes while
others led to the generation of frame shifts, premature stop
codons or splicing defects [6–8].
In this study, we identiﬁed the spectrum of mutations
causing LAD in ﬁve patients from Tunisia (North Africa)
where the population is highly inbred [9] and described two
novel mutations in the ITGB2 gene leading to the severe
form of the disease. Both mutations are single-bp deletions
resulting in frame shifts and premature termination of the
molecule. The other mutations encountered (G284S and
R593C) were already reported in patients of different eth-
nic origin except that the R593C substitution seems to have
occurred de novo in one of our patients. These two muta-
tions are probably truly recurrent mutations that with other
alreadyreportedmutationsmightdeﬁnehotspotsmutations
in the ITGB2 gene.
MATERIALS AND METHODS
Patients
Theﬁvepatientsstudied(K,I,S,R,M)werechildren(one
boyandfourgirls).Theybelongtofourunrelatedfamiliesand
were all born from related healthy parents. Patients S, R, M,
and I had the severe form and patient K the moderate form
of thedisease.Theyallhaddelayedumbilicalcordseparation
and suffered recurrent infections.1:3 (2001) Molecular basis of leukocyte adhesion deﬁciency in a north african population 115
Table 1: PCR primers used to generate ITGB2 cDNA or genomic speciﬁc DNA fragments. Nucleotide numbering is according to position
+1 being the ﬁrst nucleotide of the initiation codon ATG in the normal CD18 cDNA sequence. 5 UTR = 5  untranslated region.
Primer Sequence Nucleotide position Fragment Ampliﬁed Size of the PCR Product
1
S: 5 CTACTCCATGCTTGATGACCTA3  402-423 CD18 extracellular
1.6kb R: 5 CATCCACATAGATGAAGGTAGCG3  1973-1995 coding region
2
S: 5 GAGGAAATCGGCTGGCGAAC3  742-761
Exon 7 156bp
R: 5 ATGTTCGCTCGTTCCTTAAG3  877-896
3
S: 5 TGTGACACTGGCTACATTGGGA3  1412-1433
Exon 12 245bp
R: 5 AGACCTGGCCGTTGTAGCGC3  1636-1655
4
S: 5 GGAGGGGGCTCTGCTTCTG3  1658-1676
Exon 13 220bp
R: 5 ATGTACTTGCCACAGGGTGAG3  1858-1877
5
S: 5 CTCCTGCGCCGACTGCCT3  1879-1896
Exon 14 220bp
R: 5 CTCGGCTCTCATCCACATAG3  2079-2098
6
S: 5 ACAGAGTGCATCCAGGAGCA3  1252-1271
Exon 11 147bp
R: 5 CTCCAAGAAGCCCTTGCCAT3  1378-1397
7
S: 5 GAGTCCTTGCTCTGAAGATGACT3  −834,−812 CD18
5 UTR
1.1Kb R: 5 TGCTCTTGGTGGCAGGCACT3  230-249
Epstein-Barr virus transformed lymphoblasts were ob-
tained from each patient, their parents and few available
relatives. These cell lines were maintained in RPMI 1640
supplementedwith 20%FCS,2mMglutamineand 50µg/ml
Gentamicin at 37 ◦C in a humidiﬁed atmosphere of 5% CO2.
Flowcytometryanalysis
Control and patient peripheral blood mononuclear
cells (PBL) obtained by Ficoll-Hypaque centrifugation of
heparinized venous blood, were incubated with the anti
CD18 antibody (Immunotech, France) and the anti CD11a
(Dako M782). Expression was measured using the Becton-
DickinsonVantage cytoﬂuorometer.
Northernblot
Total cellular RNA was prepared from the patients EBV-
transformed B cells as described in [10]. Northern blot was
carried out following standard procedures [11]. A full length
normal CD18 cDNA was used as probe [12].
Oligonucleotidesused
OligonucleotidesweresynthesizedusingaBeckmanDNA
synthesizer. PCR primers used to generate ITGB2 speciﬁc
DNA fragments are shown in Table 1. The following primers
were used for DNA sequencing:
1F 5  CAAGGAGGAAGAGTGCCA3 (nct579-596)
2F 5  TTCGACTACCCATCG3 (nct895-909)
3R 5  ATGTTGTTTTCAGCCAGC3 (nct831-848)
4F 5  GCTTACAATAAACTCTCC3 (nct1075-1092)
5R 5  GACAAAGGACTGCTCCTG3 (nct1281-1264)
6F 5  CAGGTGAAGGTCACGGCC3 (nct1234-1251)
7F 5  TTGGAGTGCGGCATCTGC3 (nct1393-1410)
8R 5  CTCAGTGGTCCTCTCGCA3 (nct 1725-1742)
9F 5  TTGAGGGCTCAGCGTGCC3 (nct 1703-1720)
10R 5  ACAGGGTGAGGGGCAGCC3 (nct 1848-1866)
11F 5  CCGGCTGCCCCTCACCCTGT3 (nct 1847-1867)
Sequence-taggedsite
Genomic DNA prepared from each of the patients, their
parents and the available family members as well as 30 non-
affectedTunisiancontrols(randomlyselected),wassubjected
toampliﬁcationbyusingprimers6Sand6Rﬂankingthebial-
lelicAvaIIpolymorphism,asdescribedbyMastuuraandKishi
[13]. Primers 7S and 7R (see Table 1) ﬂanking the Xba1 site
located at the 5  end of the ITGB2 locus were designed and
used to amplify a CD18 speciﬁc 1.12Kb genomic fragment.
PCRwasperformedusing 500ngof DNA,25pmolesof each
primer and 1.5U Taq polymerase in a 50µl total volume of
10mM Tris, 50mM KC1, 1.0M MgCl2, and 200µM dNTP.
The reaction mixture was subjected to 95 ◦C for 2min fol-
lowed by 30 cycles of 94 ◦C for 1min, 62 ◦C for 50s and
72 ◦C for 1min 30s. An aliquot of 25µl of the PCR product
was digested with Xba1 and size separated on a 0.8% agarose
gel,stained with ethidium bromide and visualized under UV
illumination.
GenomicDNAampliﬁcation
Exon 7,Exon12,Exon13,andExon 14
Exon 7 and Exon 12 were ampliﬁed using, respectively,
Oligonucleotides 2S and 2R and 3S and 3R designed accord-
ingtoWeitzmanetal.[14].PCRwasperformedusing 500ng
of DNA,25pmolesof eachprimerand 1.5UTaqpolymerase
in a 50µl total volume of 1OmM Tris, 5OmM KC1, 1.0M
MgC12, and 200µM dNTP. The reaction mixture was sub-
jected to 95 ◦C for 2min followed by 30 cycles of 94 ◦C for
1min, 62 ◦C for 30s, and 72 ◦C for 1min. Exons 13 and 14116 D. M. Fathallah et al. 1:3 (2001)
wereampliﬁedinasinglefragmentusingoligos n◦6and n◦7
at the same conditions described above. Thermocycling was
as follows: 30 cycles of 94 ◦C for 1min, 60 ◦C for 1min, and
72 ◦C for 1min 30s.
RT/PCRandDNASequencing
Reverse transcription (RT) was performed on 1µgo f
total RNA or 0.5µg mRNA prepared by afﬁnity oligodT
column (Qiagen mRNA extraction kit) by ﬁrst, a 5min
incubation at 65 ◦C then transfer to ice followed by one
hour incubation at 62 ◦Ci na20µl reaction containing
0.5pM of OligodT, 0.2mM of each dNTP, 50mM Tris-HCl
pH 8, 50mM KC1, 5mM MgCl2, RNase inhibitor (Rnasin,
Boehringer Mannheim) and 1 unit of AMV reverse tran-
scriptase. The reaction was stopped by a 5min heat pulse
at 90 ◦C.
CD18 speciﬁc DNA fragments were ampliﬁed by PCR
using 10µl aliquot of the RT reaction, 1µM of each primer
in a 50µl reaction containing 2mM MgCl2, 50mM KCl,
10mM Tris-HCl, and 2.5 units of Taq Polymerase (Amer-
sham, France). Cycling was as follows: 35 cycles of 1min
at 94 ◦C, 1min at 62 ◦C, and 2min at 72 ◦C to amplify the
1.6Kb fragment using primers 1S and 1R. The Venta DNA
polymerase (New England Biolabs) was alternatively used to
generate blunt end PCR fragments that were ligated into the
pCDNA3 vector. To rule out PCR artifacts and mutations
introduced by the Taq polymerase.A minimum of four inde-
pendent PCR reactions were performed using three differ-
ent batches of enzyme and the fragments were controlled by
hybridization to an ITGB2 speciﬁc cDNA probe and/or by
restriction mapping.
Direct sequencing of PCR products was performed using
the sequenase Kit (Amersham) and the cloned PCR products
were sequenced as double stranded DNA using the same Kit
as recommended by the manufacturer (Amersham).
Parentageassessment
Paternity was established in family KH by DNA Finger-
printingusingVNTRProbes33.6and33.15(kindlyprovided
byProfA.Jeffreys,Leicester,UK)asdescribedelsewhere[15].
RESULTS
β2integrinsexpressionlevelinLADpatients
We used immunoﬂuorescence ﬂow cytometry to analyze
the level of the CD18 subunit expression on the surface of
PBMCs from ﬁve Tunisian LAD patients and their parents.
As shown in Figure 1, low levels of CD18 expression (1%t o
5%) were observed in the patients with the severe form of
the disease. Patient K had a 16.5% CD18 expression level as
compared to the normal control,which is consistent with the
moderate form of LAD. All patients exhibited a normal cell
surface expression of the leukocyte markers CD3, CD4, CD8,
CD19, and HLA DR antigens (data not shown).
Identiﬁcationofanovelpolymorphicbiallelicmarker
intheITGB2locus
An STS assay was designed to amplify a 1.1Kb genomic
DNA a fragment that contains an Xba1 site. Digestion of this
PCR product with Xba I permitted the identiﬁcation of two
alleles: 1.1kb(alleleA1orXba−)and 829bp+283bp(allele
A2 or Xba+) (see Figure 2). The Xba I alleles frequency was
0.5 for each allele within the same sample of non-affected
Tunisian individuals.
AnalysisoftheLADpatientsCD18cDNAfragments
Northernblotshowedthatallthepatientsexhibitedanor-
malsizedCD18speciﬁcmRNA(datanotshown).Weusedthe
RT/PCR strategy to generate CD18 speciﬁc cDNA fragments.
We have ﬁrst made a 1.6kb fragment corresponding to most
of theregioncodingfortheextracellulardomainof the CD18
subunit. The majority of the mutations reported to date
mapped to this region of the molecule. Sequencing of several
independently generated PCR products from each patient
revealed (see Figure 3) that all the patients have a deletion of
the G at position 1497 (1497delG) causing a frame shift and
yielding a premature stop codon, 28 residues downstream of
the deletion. Patient R was homozygous for this mutation.
PCRproductsfrombothparentssubclonedintothepCDNA3
vectorexhibitedclonesmissingtheGatposition 1497aswell
asnormalclones.ThisﬁndingisinagreementwithpatientR’s
parents being ﬁrst cousins. The second mutation, identiﬁed
in patient M, was another single-bp deletion: 1920delG that
results in a frame shift and the occurrence of a stop codon
16 residues down stream of the deletion. The third mutation
was a G to A transition affecting codon 284 (GGC/AGC)
leading to the substitution of a conserved glycine by a serine
(G284S). Patients S and I were compound heterozygous
1497delG/G284S. The G284S mutation was reported inde-
pendently in at least one unrelated patient [16]. The fourth
mutation was a single nucleotide transition in codon 593
(CGT/TGT) that leads to the replacement of the arginine
normally encoded at this position by a cysteine (R593C).
This mutation found in patient K, was reported as an
inherited mutation in two other patients,one of whom being
with certainty of different ethnic origin [16, 17]. Sequencing
of multiple RT/PCR products generated from the patient’s
parents showed that no one of them carried this mutation.
Patient K was a compound heterozygous 1497delG/R593C.
The latter occurred on a different allele than the one carrying
the 1497delG. It has previously been shown using CD18
transfection studies that the G284S and R593C mutations
prevent β2 integrin heterodimer formation and therefore
account for LAD phenotype [16, 17]. The mutations were
conﬁrmed in all the individuals studied by ampliﬁcation and
sequencing from the genomic DNA of the corresponding
codingexon:G284S(Exon7)1497delG(Exon12),1920delG,
and R593C within Exon 13 and Exon 14,respectively.
For further conﬁrmation of the de novo character of the
R593C mutation, an eventual mismatching between patient
Kandhisbiologicalparentswasruledoutbypaternitytesting
using DNA ﬁngerprinting (data not shown).
Allelicassociationanalysis
Segregation of two CD18 intragenic polymorphic mark-
ers Ava II and Xba1 with the mutations underlying LAD in1:3 (2001) Molecular basis of leukocyte adhesion deﬁciency in a north african population 117
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Figure 1: FACS analysis of the β2 integrin CD18 expression at the surface of PBMCs from Tunisian patients with leukocyte adhesion
deﬁciency (LAD). (a) control from a non-affected individual. (b), (c) and (d) represent respectively, the CD18 expression pattern obtained
in patients (I, S, R), M, and K.
1.1 Kb
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1234567
Figure 2:Polymorphism of the Xba1 site in a 1.1Kb fragment generated from the 5  region of the human ITGB2 (CD18) gene. 1.2% agarose
gelelectrophoresisof ampliﬁedDNAfromTunisianindividualsfollowingXba1restrictionenzymedigestion.Lane1:individualhomozygous
for alleleA1 (absence of the polymorphic Xba1 site). Lanes 2,3,4,and 5:individuals homozygous for alleleA2 (829 and 283bp). Lanes 6 and
7: individuals heterozygous A1/A2.
our patients was studied using site tagged sequence analysis
(STS).TheAvaIIpolymorphismwasstudiedbyanSTSassay
described elsewhere [13]. Familial studies have shown (see
Figure 4) that the 1497delG mutation, present in all the pa-
tients, segregates with the (Ava II+, Xba I+) markers. This
strong linkage desequilibrium was conﬁrmed by the study
of the patients close relatives; Chisquare = 41.5, p = 0.001
as calculated using the Four Fold Table method described118 D. M. Fathallah et al. 1:3 (2001)
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Figure 3: Detection of mutations in Tunisian LAD patients CD18 and cDNA. The DNA sequences shown were performed on cloned PCR
products obtained by RT/PCR of the patients PBMC total RNA. (a) Nucleotide sequence showing the deletion of a single G (1920delG) in
the glycine codon at position 640 causing a frame shift introducing a stop codon 16 residues downstream. The mutated CD18 protein ends
as following: GPFG FS RTAARRVRPCSCRTTP• (b) Detection of the G (1497delG) in the aspartic acid at position 500,causing a frame shift
and a stop codon 28 residues downstream. The CD18 protein is truncated as following: SCRKFS TTTPSSAQGWRTVSAG SACATPATSPAS•
(c) The C to T transition causing the substitution Arg 593 by Cyst detected in patient K is indicated by an asterisk. (d) Nucleotide sequence
showing the missense mutation that affects residue 284 of the Cd18 in patients S and S changingaCi n t oaG .FS = frame shift.
by Feiss [18]. This allelic association was present in all the
chromosomes exhibiting the 1497delG mutation and in 18
out of the 54 chromosomes studied. Interestingly, the allele
frequency of the Ava II marker in the non-affected Tunisian
population was identical to the one reported in the Japanese
population [13] (i.e., 0.7 for theAva II+ allele and 0.3 for the
Ava II-allele).
DISCUSSION
We have analyzed the molecular basis of LAD in ﬁve
patients from a highly inbred population of North Africa
(Tunisia) [9]. One patient had the moderate LAD phe-
notype and the four others had the severe one. Exten-
sive DNA sequencing of the patients ITGB2 speciﬁc cDNA1:3 (2001) Molecular basis of leukocyte adhesion deﬁciency in a north african population 119
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Figure 5: Localization of the missense mutations causing LAD,along the CD18 subunit: most of the mutations causing a single amino-acid
substitution are clustered in the NH2 domain 250 residues that are highly conserved among the β integrins (β1–β8).A Greek letter indicates
each point mutation.Asterisks (*) indicate potential hot spot mutations 1,2,3,4 are the cystein rich repeats,TM = transmembrane domain,
CD = cytoplasmic domain.
allowed the characterization of two novel mutations consist-
ing of deletions of the nucleotides G at position 1497 and
1920 (1497delG and 1920delG). Each mutation resulted in
a premature stop codon predicting the synthesis of a trun-
cated protein.
The spectrum of mutations revealed in our patients sam-
ple is peculiar in that respect that all the patients exhibited
a unique mutation: 1497delG in one allele with only one
patient being homozygous for this mutation. The obser-
vation of a preferential association between the 1497delG
mutation and Ava II+, Xba I+ alleles and the fact that all the
patients were born from consanguineous marriages,strongly
suggests the presence of a founder effect at the basis of this
mutation in our group of patients. It also suggests that this
mutation was introduced in this population on an ancestral
chromosome, tightly linked to the Ava II+, Xba+ markers.
This is the ﬁrst observation of an association between muta-
tionandpolymorphicmarkersinLADpatients.Apreviously
reported haplotype analysis in ﬁve patients showed that LAD
is not associated with a particular haplotype [19]. However,
no informations on the patients ethnic origin or their degree
of relatedness were available. The four other patients were
compound heterozygous exhibiting two different molecular
abnormalities: the 1497delG in one allele and either one of
the 1920delG, G284S, or R593C mutations in their second
allele. The R593C mutation was already reported in a patient
of different ethnic origin as a parental allele transmitted by
descent [17]. However this mutation seems to have arisen de
novo in our patient. This mutation occurs at a CPG dinu-
cleotide known to be a highly mutable dinucleotide.Another
instance of a de novo in the CD18 gene associated with LAD
phenotype was reported [20]. It concerned an A to G tran-
sition resulting in the substitution of the asparagine at posi-
tion 351 by a serine (AAT/AGT). These observations suggest
that there might be a predisposition for this type of DNA
alterationintheCD18gene.Thereportof apatienthomozy-
gous for the G284Sm u t a t i o nr e s u l t i n gf r o maGt oAt r ansi-
tion (GGC/AGC) [16] suggests that this mutation occurred
independently in our patient who is a compound heterozy-
gous G284S-1497delG. The GG dinucleotide affected by this
mutation is considered to be a highly mutable dinucleotide
according to the classiﬁcation of the dinucleotides by virtue
of theirderivedrelativemutabilityestablishedbyCooperand
Krowczack [21]. Also of interest, is the observation that the
mutation causing LAD in human (Japanese patients) and
in bovine (Holstein Cattle) [22, 23] affects the same codon:
GAC128 coding for a conserved Asparagine suggesting that
the codon at this position might be more susceptible to mu-
tagenesis. Other instances of probably recurrent mutations
in the CD18 (see Figure 5) are observed and affect residues
L149 (L149P: CTA/CCA) (see [16, 24, 25]), G169 (G169R:
GGG/AGG)[24,26],andR586(R586W:CGT/TGT)[16,20].
The high propensity to mutate of some of the ITGB2 gene
codons,where de novo and recurrent mutations occurred,ar-
gues in favor of these sites being potential mutational “Hot
spots.”Interestingly,mostof thesehotspotsareclusteredina
250 amino-acid domain of the CD18 molecule that is highly
conserved among the β (β1–8) integrins [12]. This region
of the CD18 molecule is sought to be involved in the asso-
ciation of the α and β subunits. Furthermore, the elevated
number and the nature of the mutations (de novo, recur-
rent) affecting the ITGB2 gene as well as their distribution
suggest that this gene might be prone to spontaneous muta-
tions.
Under this assumption, the frequency of morbid alleles
in highly inbred populations should be higher than the one
observed, and screening for heterozygous carriers especially
inaffectedfamilieswithextendedpedigreeshouldprovetobe
useful.Otherchildren(ﬁve)withboththemildandthesevere
formofLADwerediagnosedduringandafterageneticsurvey
intheareafromwheretheﬁrstpatientsoriginated(Fathallah
and Bejaoui,unpublished data).1:3 (2001) Molecular basis of leukocyte adhesion deﬁciency in a north african population 121
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